Artificial gravity maintains skeletal muscle protein synthesis during 21 days of simulated microgravity.
We sought to determine the effects of longitudinal loading (artificial gravity) on skeletal muscle protein kinetics in 15 healthy young males after 21 days of 6 degrees head-down tilt bed rest [experimental treatment (Exp) group: n = 8, 31 +/- 1 yr; control (Con) group; n = 7, 28 +/- 1 yr, means +/- SE]. On days 1 and 21 of bed rest, postabsorptive venous blood samples and muscle biopsies (vastus lateralis and soleus) were obtained during a 1-h pulse bolus infusion protocol (0 min, l-[ring-(13)C(6)]phenylalanine, 35 mumol/kg; 30 min, l-[ring-(15)N]phenylalanine, 35 mumol/kg). Outcome measures included mixed muscle fractional synthesis (FSR) and breakdown rates (FBR). The Exp group experienced 1 h of longitudinal loading (2.5G at the feet) via a short-radius centrifuge during each day of bed rest. Mixed muscle FSR in the Con group was reduced by 48.5% (day 1, 0.081 +/- 0.000%/h vs. day 21, 0.042 +/- 0.000%/h; P = 0.001) in vastus lateralis after 21 days of bed rest, whereas the Exp group maintained their rate of protein synthesis. A similar but nonsignificant change in FSR was noted for the soleus muscle (Exp, -7%; Con, -22%). No changes in muscle protein breakdown were observed. In conclusion, 1 h of daily exposure to artificial gravity maintained the rate of protein synthesis of the vastus lateralis and may represent an effective adjunct countermeasure to combat the loss of muscle mass and functional during extended spaceflight.
Symons
T B
TB
The Univ. of Texas Medical Branch, 301 Univ. Blvd., Galveston, TX 77555-1144, USA.
Sheffield-Moore
M
M
Chinkes
D L
DL
Ferrando
A A
AA
Paddon-Jones
D
D
D000328:Adult; D001510:Bed Rest / Q000009:adverse effects; D018470:Gravity, Altered; D018475:Head-Down Tilt / Q000009:adverse effects; D006801:Humans; D008297:Male; D009124:Muscle Proteins / Q000096:biosynthesis*; D018482:Muscle, Skeletal / Q000378:metabolism*; D009133:Muscular Atrophy / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D020966:Muscular Disorders, Atrophic / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D016474:Weight-Bearing / Q000502:physiology; D014893:Weightlessness / Q000009:adverse effects; D018544:Weightlessness Countermeasures
D009124:Muscle Proteins